ONXX
Pues dividiendo el precio entre las acciones sale a un precio de 141,80/acción. Y ahora mismo las ofrecen a 123,75 en pre. (+5,68%, hace un rato 6,xx%). ¿Se me escapa algo?
¿15 $ por tus calzoncillos de la suerte? Compro.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Cuarto y último fabrica-pastis para AMRN
Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Novasep Group, S.A.S., through its subsidiary Finorga S.A.S., as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.
Novasep, a global leader in purification technologies and API manufacturing, is building the world's largest chromatography plant using its proprietary chromatography technologies to produce API on behalf of the Slanmhor consortium and Amarin. Amarin anticipates the Novasep facility, located in Mourenx, France, to be qualified and operational for manufacturing in 2014.
"This sNDA submission for Novasep brings to four the total number of suppliers that are approved or in regulatory review for Vascepa API production, including Nisshin Pharma, Inc. and following the recent FDA approvals of both BASF and Chemport as API suppliers for the product," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "The Novasep submission represents an additional step toward the goal of expanding our global supply chain to support expected Vascepa demand, diversify our supply base and ensure cost-efficient supply. As previously stated, the continued addition of these suppliers will potentially lead to API cost reductions of up to 50% or more and help us reach a steady state gross margin as a percentage of product revenues in the high seventies to low eighties."
This submission contributes to the planned expansion of the Vascepa manufacturing supply chain and is additional progress toward Amarin's goal to protect the commercial potential of Vascepa to beyond 2030 through a combination of patent protection, regulatory exclusivity, trade secrets and by taking advantage of manufacturing barriers to entry. Along with this planned expansion in supply, Amarin's significant progress includes expansion of patent protection for Vascepa in the United States with 27 Amarin patents either issued or allowed and over 30 additional patent applications being prosecuted in the United States. Amarin is also making significant progress with its patent applications related to Vascepa in multiple jurisdictions outside the United States, including the May 2013 patent grant by the European Patent Office covering the use of Vascepa based on the results from the MARINE trial.
no vayas tan rápido, campeona, 15$xcfd.
pero a ti, te haria un precio especial..... o quizás un cambio.
;-)))
Y dices que yo soy rápida... A ver, ¿cuáles son las condiciones cambio? Envíame una foto del producto que lo tase.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that it will be a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Cellceutix will be presenting on Monday, September 9 at 2:00 PM EDT. The conference is being held at the Millennium Broadway Hotel in New York City from September 8 - September 10.
"We are very pleased to once again be presenting at the Rodman and Renshaw annual investment conference," said Leo Ehrlich, chief executive officer at Cellceutix. "In a live webcast for institutional and other investors, we will be providing the current status of the clinical trials of our anti-cancer drug, Kevetrin™, hosted at Harvard's Dana-Farber Cancer Institute as well as an update on the impending clinical trial of our anti-psoriasis drug, Prurisol, and other corporate developments. Our presentation last year was extremely well received and we hope that this year's corporate update will have a similar response."
CTIX
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Garmen Laboratories has a strict quality assurance program that meets 21CFR211 (GMP) and ISO 17025 environment. It is a U.S. Food and Drug Administration-registered facility and accredited by Health Canada. More on Garmen Labs can be found at www.garmen.ca.
Garmen Laboratories will manufacture 1 kilogram of Adva-27a, Sunshine Biopharma's flagship anticancer drug candidate in development for multidrug resistant cancers. The 1-kilogram GMP material will be used to complete the remaining studies required to file an Investigational New Drug application with the U.S. Food and Drug Administration and conduct the Breast Cancer Phase I clinical trial of Adva-27a scheduled to be hosted at McGill University's Jewish General Hospital in Montreal, Canada.
Recently, Advanomics received $1.45 million in research grants from the distinguished Canadian granting agencies, NSERC, NanoQuebec and Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a.
"We are extremely pleased with the acquisition of Garmen Laboratories as it puts us in a prime position to continue to advance our novel cancer drug," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are excited that our methodical business plan in the development of Adva-27a is coming to fruition. The recent grants have us in a sound financial condition and the new acquisition provides us with complete control of the manufacturing process, an envious position for any small biotechnology company."
SBFM
Volverás a entrar hoy?
Me la he mirado, y he observado que en algún foro hablan de que puede recuperar rápidamente los 10$...
CCXI
ONXX
Se anuncia precio de 125 $.
Las acciones de Amgen suben un 7,88% después de acordar comprar la compañía Onyx Pharmaceuticals (ONXX 5,58%) en una operación que le dará acceso a los productos anti-cancerígenos.
Amgen pagará 125 dólares por acción de Onyx en efectivo y espera que el acuerdo se cierre a principios del cuarto trimestre.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
